SCHEMBL4178397

SCHEMBL4178397

N#C/C(=C\c1ccc(O)cc1O)S(=O)(=O)Cc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.43
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
EGFR P00533 6/20 0.37
MAOB P27338 1/20 0.37
LCK P06239 1/20 0.36
ERBB2 P04626 2/20 0.36
SLC5A1 P13866 1/20 0.35
SLC5A2 P31639 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178400 1.00 MIF (0.43) MIFLMNAHTTSMN1; SMN2KDM4E
SCHEMBL4178406 1.00 MIF (0.43) MIFLMNAHTTSMN1; SMN2KDM4E
SCHEMBL4173138 0.88 HSP90AA1 (0.44) MIFMAPTEGFRMAOBLCK
SCHEMBL4173145 0.88 HSP90AA1 (0.44) MIFMAPTEGFRMAOBLCK
SCHEMBL4173142 0.88 HSP90AA1 (0.44) MIFMAPTEGFRMAOBLCK
SCHEMBL4184784 0.79 GABRA1 (0.47) LMNASMN1; SMN2MAPTPKML3MBTL1
SCHEMBL4184775 0.79 GABRA1 (0.47) LMNASMN1; SMN2MAPTPKML3MBTL1
SCHEMBL4184782 0.79 GABRA1 (0.47) LMNASMN1; SMN2MAPTPKML3MBTL1
SCHEMBL4172185 0.78 PKM (0.44) LMNAHTTMAPTPKML3MBTL1
SCHEMBL4172179 0.78 PKM (0.44) LMNAHTTMAPTPKML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-07-30 US claimed
EP-2046322-A2 ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2009-04-15 EP claimed
WO-2008016682-A2 ARYL VINYL SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-02-07 WO claimed
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090191193-A1 Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof ARSA, STS, SULT2A1 MIF 3495/4885LMNA 4621/4885HTT 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.